Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon.
about
Immune responses to Cryptosporidium muris and Cryptosporidium parvum in adult immunocompetent or immunocompromised (nude and SCID) miceNonionic block copolymers potentiate activities of drugs for treatment of infections with Toxoplasma gondiiThe protein kinase double-stranded RNA-dependent (PKR) enhances protection against disease cause by a non-viral pathogen.Changes in cytokine levels during reactivation of Toxoplasma gondii infection in lungs.Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection.Immune CD8(+) T cells prevent reactivation of Toxoplasma gondii infection in the immunocompromised host.Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii.Contribution of interleukin-12 (IL-12) and the CD28/B7 and CD40/CD40 ligand pathways to the development of a pathological T-cell response in IL-10-deficient mice.Exacerbated susceptibility to infection-stimulated immunopathology in CD1d-deficient mice.Antibody against interleukin-6 reduces inflammation and numbers of cysts in brains of mice with toxoplasmic encephalitis.Different strains of Toxoplasma gondii induce different cytokine responses in CBA/Ca miceMechanisms of innate resistance to Toxoplasma gondii infection.Gut intraepithelial lymphocytes induce immunity against Cryptosporidium infection through a mechanism involving gamma interferon productionEmergence of NK1.1+ cells as effectors of IFN-gamma dependent immunity to Toxoplasma gondii in MHC class I-deficient mice.Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondiiSequential analysis of cell differentials and IFN-gamma production of splenocytes from mice infected with Toxoplasma gondii.Toxoplasma gondii cyclophilin 18-mediated production of nitric oxide induces Bradyzoite conversion in a CCR5-dependent manner
P2860
Q24648152-87201B0F-45C5-4FDA-A33A-252906301C3FQ28378795-11A328A3-B1E0-4637-8410-71470FD53F98Q31129671-77FA49FD-D53D-46BD-9310-5B82F889C3C6Q33866599-78C21668-1010-43F5-8B53-00B30C75B896Q33975360-AC10497D-6A49-4B77-B433-E5412FC36A3DQ34002460-37659EA7-7BB7-4F0E-BAA7-A4C994C448DAQ34006385-E15A6F02-105E-4178-A0DF-917B828EF6D9Q34262167-B11128A4-3514-4233-AD3A-3689D96A8688Q34440132-DF6FDF86-F35B-40CB-BFBB-189ADEDDC57CQ34529261-FD230063-2754-461A-925E-4724B8828494Q35106186-80BA0168-6E4E-442A-B225-55FA3348C8C2Q35211714-B0BB3764-6A3B-4EFF-A083-E9AB7F106B8CQ35552090-CF165D80-D054-4DEB-AC1E-67AF86314451Q36362549-F37A907F-BD49-4CF8-A369-B726D0F3EA81Q36377044-0EB128AE-28B6-4B70-8FFB-2AF36DAB47BAQ37289969-758D98D4-2855-4F28-90B4-C48803CBE31FQ37333376-426C2DEA-CCEC-4023-A70C-CF7D17DD6D89
P2860
Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon.
description
1990 nî lūn-bûn
@nan
1990 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon.
@ast
Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon.
@en
type
label
Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon.
@ast
Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon.
@en
prefLabel
Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon.
@ast
Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon.
@en
P2093
P2860
P1476
Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon.
@en
P2093
F K Conley
J S Remington
P2860
P304
P407
P577
1990-09-01T00:00:00Z